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1. Introduction
The presence of pharmaceuticals in groundwater 
has been widely studied and discussed over the 
past few years (Seiler et al., 1999; Sacher et al., 2001; 
Kolpin et al., 2002; Cordy et al., 2004; Verstraeten 
et al., 2005; Barnes et al., 2008; Zuccato et al., 2008; 
Loos et al., 2010; Vulliet & Cren-Olive, 2011; Lap-
worth et al., 2012; Stuart et al., 2012; Gaffney et al., 
2015; Lopez et al., 2015; Lapworth et al., 2019). Their 
presence is most commonly associated with pollu-
tion from communal wastewater (Seiler et al., 1999; 
Verstraeten et al., 2005) as well as with agriculture 
because veterinary medicines can often be found 
in manure, used as a natural fertiliser (Lapworth 
et al., 2012; Stuart et al., 2012). Pharmaceuticals 
are one of many substances known as anthropo-
genic organic compounds that have only recently 
been recognised as a growing threat to ground-
water resources. Their occurrence and fate in the 
environment are not well understood and mostly 
not regulated; however, increasingly more studies 
confirm the growing problem of their presence in 
both groundwater and surface water. For that rea-
son, pharmaceuticals were one of the first groups of 
emerging contaminants that have been considered 
for detailed analysis when developing a method-
ology for a groundwater watch list for substances 
of emerging concerns (Lapworth et al., 2019). Such 
watch list is a consequence of the 2014 review of the 
EU Groundwater Directive Annexes (Commission 
Directive 2014/80/EU) during which the need to 
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obtain and respond to new information on other 
substances that pose a potential risk was officially 
acknowledged. As such the Commission delegated 
the task of developing such a watch list to expert 
groups who work under the Common Implementa-
tion Strategy for Directive 2000/60/EC.
In Poland, studies of pharmaceutical content 
in groundwater are not widespread. However, 
the few research results available have confirmed 
the validity of their implementation (Caban et al., 
2015; Kmiecik et al., 2017a, 2017b; Kuczyńska, 2017; 
Kuczyńska & Janica, 2017). In 2016-2017, the Polish 
Geological Institute - National Research Institute 
conducted a pilot study of the content of pharma-
ceuticals in groundwater throughout the country. 
The first part of the research was carried out on the 
occasion of implementation of surveillance moni-
toring in 2016, at the request of the Chief Inspec-
torate of the Environment (Kuczyńska, 2017). This 
proved the presence of active pharmaceutical sub-
stances in > 60 per cent of 93 samples selected for 
analytical studies. The study was continued in 2017, 
albeit to a smaller extent due to budget cuts. In 2017 
sampling was carried out during operational and 
research monitoring at the request of the Chief In-
spectorate of the Environment and the National 
Water Management Board. In both years, sampling 
was funded by the National Fund for Water Man-
agement and Environmental Protection. The costs 
of laboratory analyses were paid for as part of the 
PGI-NRI’s statutory research scheme that is funded 
by the Ministry of Science and Higher Education. 
For the present paper data from the 2-year pilot 
were analysed together and are presented in the 
light of land use, together with a comparison with 
results of other monitoring data.
2. Methodology
2.1. Sampling
The pilot study on pharmaceutical content in 
groundwater was undertaken during two sampling 
campaigns in the years 2016-2017. In 2016 sampling 
was carried out on the occasion of surveillance mon-
itoring across the entire country, in all groundwater 
bodies (172). The total number of monitoring bore-
holes covered during the surveillance campaign 
was 1,266. Of these, 105 monitoring boreholes were 
selected for determination of pharmaceuticals. Lo-
cations of sampling points were carefully studied to 
reflect potential pollution sources associated with 
the proximity to urban agglomerations or rural ar-
eas (poor sewage networks, spread of manure), or 
close to documented outbreaks of pollution, e.g., a 
cemetery, a hospital, sewage treatment plants, or 
a short distance from surface water courses. The 
depth to the water-bearing zone and borehole logs 
were analysed to ensure that sampling locations 
could have been exposed particularly to the im-
pact of municipal anthropogenic pressure due to 
the shallow occurrence of water-bearing horizons, 
devoid of isolation. During the initial selection, 105 
wells were selected to meet the above assumptions, 
while sampling attempts were made in 98 boreholes. 
For technical reasons (no possibility of sampling) 
and random (damage to samples during transport), 
samples collected in 93 selected locations were ana-
lysed. These points were located within an area of 60 
groundwater bodies, 98 per cent of which are with-
in porous Quaternary formations. Sixteen out of 
60 groundwater bodies covered by this studywere 
defined at the risk of not achieving environmental 
goals in river basin management plans for 2016-2021 
(Regulation of the Council of Ministers, Dz. U. 2016 
poz. 1818, poz. 1911, poz. 1914, poz. 1915, poz. 1917, 
poz. 1918, poz. 1919, poz. 1929, poz. 1959, poz. 1967).
In 2017 sampling was carried out within the 
framework of operational and research monitoring. 
The operational monitoring was done in 392 mon-
itoring boreholes located within 66 groundwater 
bodies, including 39 GWBs that were defined at the 
risk of not achieving environmental goals in river 
basin management plans for 2016-2021 and 27 GWBs 
were included in the monitoring of nitrate-vulner-
able zones 2012-2015. In total 50 sampling points 
were selected and samples collected from 46 of 
these. An additional set of 21 samples was collected 
from a network serving research monitoring that is 
destined to monitor water quality in areas of poten-
tial environmental problems linked with industrial 
activities or large accumulation of pollution sources 
such as agglomerations. Again, depth to the wa-
ter-bearing zone and borehole logs were analysed 
to ensure that sampling locations could have been 
particularly exposed to the impact of municipal an-
thropogenic pressure due to the shallow occurrence 
of water-bearing horizons, devoid of isolation. In 
total 67 samples were collected for the 2017 study. 
There were no duplicate sampling locations over 
those two years and in both years collections were 
made between April and October. The total number 
of samples analysed was 160.
Water samples were collected in accordance with 
accreditation rules for the collection of groundwater 
samples held by the Polish Geological Institute-Na-
tional Research,and in line with the PN-EN ISO 
5667-11:2004P standard. To collect representative 
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groundwater samples, monitoring boreholes were 
cleaned and pumped out using suction pumps prior 
to water sampling. Temperature stability, pH and 
conductivity were monitored in order to confirm 
the inflow of fresh water from an aquifer to the sam-
pling wells. Depending on the stability of the pa-
rameters monitored, the volume of water pumped 
from wells varied from 3 to 5 volumes of stagnant 
water. Water samples were collected into three 1-li-
tre bottles of pharmaceutical glass. Bottles and cups 
were rinsed with water before a water sample was 
taken. Water was kept under a cork, under which 
an aluminium foil was placed to protect against 
sorption of more non-polar analytes. Bottles with 
water samples were transported to the laboratory in 
thermal containers equipped with cooling cartridg-
es. Samples were delivered to the laboratory within 
24 hours of sampling.
2.2. Chemical analysis
The scope of analytical tests included 34 active sub-
stances of the following groups of drugs:
 – Oestrogenic hormones: estrone, estriol, 17α-ethi-
nylestradiol (EE2), 17β-estradiol (E2), testoster-
one;
 – β-blockers (drugs against cardiovascular dis-
ease): nadolol (2016), atenolol (2017), metopro-
lol, pindolol, propranolol;
 – β-agonists (medicines against respiratory dis-
eases): terbutaline, salbutamol;
 – Analgesics and anti-inflammatory drugs: di-
clofenac, ibuprofen, ketoprofen, naproxen, par-
acetamol, flurbiprofen;
 – Antidepressants: imipramine, clomipramine, 
doxepine (2016 only), amitriptyline (2017 only);
 – Antimicrobial agents (sulfonamides and anti-
biotics): sulfadiazine, sulfadimethoxine, sul-
famerazine, sulfamethazine, sulfamethoxazole, 
sulfapyridine and sulfathiazole, sulfachloropiri-
dazine and trimethoprim, enrofloxacin;
 – Anti-epileptics: carbamazepine;
 – Caffeine (2017 only).
Chemical analyses were done at the Faculty of 
Chemistry of the University of Gdańsk in the Lab-
oratory of Analytical and Environmental Monitor-
ing using gas and liquid chromatography (Caban 
et al., 2012; Borecka et al., 2015; Caban et al., 2015). 
The sample preparation step included a high-vol-
ume solid phase extraction using accelerated ex-
traction discs and derivatisation (GC/MS method 
only). The final determinations were made using 
two techniques, depending on the group of drugs. 
Oestrogenic hormones, β-blockers, β-agonists, an-
algesics and tricyclic antidepressants were deter-
mined by gas chromatography coupled with mass 
spectrometry (GC/MS) in the mode of selected ion 
monitoring (SIM). Antimicrobial drugs, carbamaze-
pine and caffeine were determined using high-per-
formance liquid chromatography coupled with tan-
dem mass spectrometry (LC-MS/MS) in the MRM 
recording mode. Quality of results was achieved by 
instrumental and methodological validation, which 
Table 1. Metrological parameters of analytical methods of compounds using GC /MS (SIM) and LC-MS/MS (MRM).
Pharmaceuticals Year Range of linearity1 (ng/dm3) MQL2) (ng/dm3) R3) RSD4) Recovery5) (%)
17alfa-etynyloestradiol (EE2) 2016 10–100 10 0.9998 3.64–3.45 95.8–109.5
2017 5–100 5 0.9996 2.1–7.3 65.3–110.0
17beta-estradiol (E2) 2016 5–100 5 0.9997 0.81–1.62 82.6–109.1
2017 5–100 5 0.9998 5.3–7.7 93.6–113.8
Amitryptyline 2017 10–100 10 0.9999 5.0–8.5 95.1–111.5
Atenolol 2017 1–100 1 0.9988 1.2–6.4 94.7–102.16
Diclofenac 2016 5–100 5 0.9997 0.32–3.23 82.9–100.1
2017 5–100 5 0.9999 5.0–6.9 88.3–111.6
Doxepine 2016 5–100 5 1.0000 0.65–1.98 91.6–104.4
Enrofloxacin 2016 5–100 5 0.9997 0.82–1.80 83.3–108.9
2017 5–100 5 0.9998 2.47–6.18 95.1–101.7
Estriol 2016 5–100 5 0.9996 1.55–3.70 70.6–101.6
2017 5–100 5 0.9999 07.1–13.1 84.8–108.6
Estrone 2016 5–100 5 0.9998 2.92–7.37 84.9–110.5
2017 5–100 5 0.9993 2.0–8.0 87.7–113.9
Flurbiprofen 2016 5–100 5 0.9999 1.71–2.97 79.1–115.3
2017 5–100 5 0.9998 1.4–5.0 89.6–115.6
Ibuprofen 2016 5–100 5 0.9991 1.60–1.83 81.2–116.6
2017 5–100 5 0.9998 4.4–5.2 93.8–112.6
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Pharmaceuticals Year Range of linearity1 (ng/dm3) MQL2) (ng/dm3) R3) RSD4) Recovery5) (%)
Imipramine 2016 5–100 5 0.9998 1.73–6.64 88.1–109.9
2017 5–100 5 0.9993 1.8–7.8 80.7–111.9
Carbamazepine 2016 1–100 1 0.9997 1.65–6.21 81.8–108.9
2017 1–100 1 0.9993 0.96–5.68 92.3–103.8
Ketoprofen 2016 5–100 5 0.9999 1.86–4.42 85.1–102.0
2017 5–100 5 1.0000 3.0–8.1 88.0–109.9
Clomipramine 2016 10–100 10 0.9998 1.69–8.01 88.1–106.4
2017 10–100 10 0.9990 5.8–10.6 95.6–113.9
Caffeine 2017 5–100 5 1.0000 5.12–8.97 80.3–104.6
Metoprolol 2016 1–100 1 0.9998 0.23–6.81 90.9–115.3
2017 10–100 10 0.9890 3.9–4.3 96.9–118.1
Nadolol 2016 1–100 1 1.0000 0.54–4.74 93.6–101.7
Naproxen 2016 5–100 5 0.9996 0.17–3.58 72.9–105.3
2017 5–100 5 0.9999 2.4–7.5 89.0–103.4
Paracetamol 2016 5–100 5 1.0000 4.56–8.68 98.4–109.6
2017 5–100 5 0.9999 1.6–7.9 86.3–115.2
Pindolol 2016 10–100 10 0.9998 3.26–8.01 83.0–11.1.
2017 10–100 10 0.9850 4.0–6.8 89.2–137.3
Propranolol 2016 5–100 5 1.0000 0.10–3.52 97.7–102.7
2017 5–100 5 0.9990 0.9–7.5 96.5–112.0
Salbutamol 2016 5–100 5 0.9975 1.39–4.77 97.9–121.1
2017 5–100 5 0.9979 5.2–6.6 68.3–102.4
Sulfachloropiridazine 2016 1–100 1 0.9999 0.43–5.22 96.7–117.9
2017 1–100 1 0.9999 2.70–7.94 95.5–114.8
Sulfadiazine 2016 1–100 1 0.9999 1.99–5.38 95.6–108.5
2017 1–100 1 0.9998 1.74–5.73 84.8–117.0
Sulfadimethoxine 2016 1–100 1 0.9998 3.66–7.90 91.7–102.2
2017 1–100 1 1.0000 1.45–5.91 97.7–116.5
Sulfamerazine 2016 1–100 1 0.9998 4.08–8.97 89.9–101.9
2017 1–100 1 0.9999 2.62–6.45 95.2–112.0
Sulfamethazine 2016 1–100 1 1.0000 3.30–6.76 95.6–100.4
2017 1–100 1 0.9998 1.40–4.26 92.6–102.0
Sulfamethoxazole 2016 1–100 1 1.0000 0.85–8.11 99.1–111.8
2017 1–100 1 0.9997 2.32–5.72 91.4–102.5
Sulfapiridine 2016 1–100 1 1.0000 2.71–8.56 98.8–103.7
2017 1–100 1 0.9994 1.47–4.29 84.3–100.2
Sulfathiazole 2016 1–100 1 0.9997 2.36–6.09 92.7–128.4
2017 1–100 1 0.9999 1.96–6.50 98.9–103.9
Terbutaline 2016 5–100 5 1.0000 1.00–2.18 98.4–100.0
2017 5–100 5 0.9998 4.0–8.7 87.0–113.8
Testosterone 2016 30–100 30 0.9999 1.82–6.74 94.0–99.6
2017 50–100 50 0.9999 4.0–7.8 60.7–105.2
Trimetoprim 2016 1–100 1 0.9998 0.94–9.10 93.9–111.5
2017 1–100 1 0.9990 2.19–7.29 86.0–116.7
1)Range of linearity – range of the analytical method in which the output signal is proportional to the analyte being 
determined.
2)MQL – method quantification limit; the lowest concentration of the substance possible to quantify by a given analytical 
method with assumed precision and accuracy.
3)R – correlation coefficient; a statistical measure that characterises linearity and defines the relationship between test 
results and concentrations of the substance.
4)RSD – relative standard deviation; a statistical measure that defines the dispersion of a data set relative to its mean.
5)Recovery – part of the substance recovered from the sample tested, determined on the basis of measurements of the 
substance in enriched and non-enriched samples.
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was done in the same way for both analytical meth-
ods. A known amount of the analyte mixture at con-
centrations of 1-100 ng/dm3 was added to tap water 
samples with a conductivity similar to the samples 
tested, then subjected to extraction and instrumen-
tal analysis similar to the analysis of groundwater 
samples. Based on the results, metrological parame-
ters of analytical methods were calculated (Table 1). 
Method quantification limits (MQL) differed from 1 
to 50 ng/dm3, and were lower for the high-perfor-
mance liquid chromatography technique coupled 
with tandem mass spectrometry (LC-MS/MS). The 
highest MQL limits concerned testosterone in GC/
MS (SIM) technology and amounted to 30–50 ng/
dm3, and enrofloxacin and caffeine in LC-MS/MS 
(MRM) technology to 5 ng/dm3.
3. Results
3.1. Detection of pharmaceuticals
Pharmaceuticals were detected at 85 locations, 
which amounts to 53 per cent of all sampling 
points. In total, 24 out of 34 analytes that were in-
cluded in the 2-year study were detected in water 
samples. The following ten substances were not de-
tected in any sample: nadolol, atenolol, pindolol, 
terbutaline, doxepine, imipramine, clomipramine, 
amitriptyline, sulfachloropiridazine and trimeth-
oprim (Table 2, Fig. 1). The most commonly seen 
substance was carbamazepine, which was found 
in a total of 33 monitored locations (21 per cent of 
all boreholes samples). Carbamazepine is an anti-
Table 2. Number of positive detections and maximum concentrations of specific pharmaceuticals analysed in the pres-
ent study
No. Pharmaceuticals No. of sites with detection
No. of sites with de-
tection below MQL




1 Estrone 3 0 3 69
2 Estriol 1 0 1 5
3 17α-etynyloestradiol (EE2) 2 0 2 61
4 17α-etynyloestradiol (EE2) 1 0 1 10
5 Testosterone 2 2 0
6 Nadolol 0
7 Atenolol 0
8 Metoprolol 1 0 1 5
9 Pindolol 0
10 Propranolol 3 1 2 28
11 Terbutaline 0
12 Salbutamol 1 1 0
13 Diclofenac 9 3 6 42
14 Ibuprofen 19 10 9 599
15 Ketoprofen 5 0 5 27
16 Naproxen 4 2 2 40
17 Paracetamol 4 2 2 52





23 Caffeine 1 0 1 641
24 Carbamazepine 33 0 33 869
25 Sulfadiazine 5 0 5 28
26 Sulfadimethoxine 10 4 6 6
27 Sulfachloropiridazine 0
28 Sulfamerazine 4 0 4 105
29 Sulfamethazine 5 3 2 31
30 Sulfamethoxazole 20 0 20 66
31 Sulfapyridine 7 2 5 23
32 Sulfathiazole 1 0 1 2
33 Enrofloxacin 14 10 4 7
34 Trimethoprim 0
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convulsant medication used primarily in the treat-
ment of epilepsy and neuropathic pain. It is also 
used to treat schizophrenia and bipolar disorder. 
It is very mobile and persistent and therefore of-
ten found in groundwater (Lapworth et al., 2012; 
Lopez et al., 2015; Lapworth et al., 2019). All con-
centrations detected during the present study were 
quantified and varied from 1 to 869 ng/dm3. The 
highest value was found in a shallow borehole 
drilled in Quaternary sands in a small town east 
of Warsaw. Other studies have reported maximum 
concentrations in groundwater varying from c. 99 
to 900 ng/dm3 (Sacher et al., 2001; Focazio et al., 
2008; Lapworth et al., 2012). The second most com-
monly found substance was the human and veter-
inary antibiotic sulfamethoxazole. Sulfamethoxaz-
ole results in high concentrations in urine, hence 
is a good indicator of sewage. The substance was 
found in 20 sampling locations (13 per cent) with 
concentrations varying between 1 and 66 ng/dm3. 
The highest concentration was found in a shallow 
borehole screened in sands in a touristic/rural area 
in northern Poland. Sulfamethoxazole was also the 
second most commonly found pharmaceutical re-
ported in Lapworth’s review of 2012 (Lapworth et 
al., 2012), where it was reported at a maximum of 
1,100 ng/dm3. Lopez et al. (2015) noted sulfameth-
oxazole to be the most frequently quantified anti-
biotic in France. The pain relief and anti-inflamma-
tory drug ibuprofen was the third most commonly 
found drug that was detected in 19 locations (12 
per cent); however, in 10 of these concentrations 
were found to be too low to quantify (i.e., marked 
as below method quantification limit). Quantifiable 
concentrations varied between 5 and 599 ng/dm3. 
Ibuprofen was also the third most commonly found 
pharmaceutical reported by Lapworth et al. (2012), 
who noted maximum concentrations of 12,000 ng/
dm3. In the USA maximum concentrations were re-
ported at 3,110 ng/dm3 (Barnes et al., 2008). Sacher 
et al. (2001) also looked for ibuprofen in Germany, 
but did not report any positive findings. The veter-
inary antibiotic enrofloxacin was found in 14 sam-
pling locations, which accounts for nine per cent of 
all sampling locations; however, at only 4 locations 
concentrations were found at quantitative levels 
and these varied between 5 and 7 ng/dm3. This 
antibiotic was also studied by Barnes et al. (2008) 
in the USA, but not detected. Another veterinary 
antibiotic, sulfadimethoxine, was found in 10 loca-
tions (6 per cent). Quantified concentrations were 
detected in 6 of these, varying between 1 and 6 
ng/dm3. Sulfadimethoxine was also studied in the 
USA by Barnes et al. (2008), but not detected. Di-
Fig. 1. Distribution of pharmaceuticals in water samples collected for the present study in 2016 and 2017
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clofenac was the second most common drug, after 
ibuprofen, of the group of analgesics and anti-in-
flammatory drugs. It was detected in nine sampled 
locations; in three samples concentrations were at 
levels below MQL. Concentrations varied from 5 
to 42 ng/dm3. Lapworth et al. (2012, 2019) reported 
maximum concentrations of 590 ng/dm3 and also 
found diclofenac to be the second most common-
ly analysedpharmaceutical in groundwater across 
Europe, albeit with low detection rates. Flurbipro-
fen and sulfapyridine are the last pharmaceuticals 
among the drugs that were found at more than 
five sampling points. Flurbiprofen is a non-steroid, 
anti-inflammatory drug commonly used for treat-
ment of rheumatoid problems. It was detected at 
seven sampling locations (4 per cent) and concen-
trations were quantified in two of them ranging be-
tween 5 and 22 ng/dm3. Sulfapyridine is a human 
antibiotic. It was detected at seven sites, at five of 
which it was quantified at concentrations ranging 
from 1 to 23 ng/dm3. All other drugs were found at 
a maximum of five locations.
3.2. Distribution of pharmaceuticals in 
relation to land use
All sampling locations were categorised with re-
spect to land use based on the most recent infor-
mation from CORINE Land Cover system (2018) 
and information provided by field technicians. 
To simplify categorisation of land use types, sam-
pling points were assigned to five land use classes, 
namely: forests, meadows, industrial and dense 
urban areas, agricultural areas (villages and crop 
fields) and urban areas with scattered buildings. 
Sampling locations located in meadows and forests 
were usually associated with foresters’ buildings 
or other touristic premises of occasional usageand 
agro-tourism. This study was aimed at sites with 
high potential for documentation of pharmaceuti-
cals due to land use and construction of sampling 
boreholes. Statistics demonstrated a high potential 
for the presence of pharmaceuticals at all types 
of land use (Table 3). However, the land use type 
that proved to be the most prone to pollution with 
pharmaceuticals are agricultural areas. This is the 
type of use that was also most extensively covered 
by the present study. Fifty-two per cent of all sam-
pling sites were located in rural areas and 55 per 
cent of them showed positive detection of pharma-
ceuticals. This is due mainly to poor sewage man-
agement in rural areas, often based on septic tanks 
and use of trickled systems, as well as manure dis-
tribution as part of agricultural practice. A similar 
situation was found in urban areas with scattered 
buildings. Fifty-nine per cent of all sites located in 
this land use type were proved to be polluted with 
pharmaceuticals. Sampling locations in meadows 
and forests were separated from agricultural use 
and are located in places where pressure from agri-
culture is considered low; yet, results showed that 
they are also subjected to pollution from anthropo-
genic sources.
The distribution of specific types of drugs at 
different land use type is presented in Table 4. The 
highest number of different drugs (21 substances) 
was found in agricultural areas. The most com-
monly detected drugs here were sulfametoxazole 
(an antibiotic for human and veterinary use alike), 
ibuprofen and carbamazepine. They were found 
at 17, 16 and 13 per cent of sites, respectively. Oth-
er, less common drugs found are sulfadimetoxine 
(10 per cent of sites) and enrofloxacin (8 per cent 
of sites), which are both veterinary antibiotics. In 
urban areas with scattered buildings a total of 20 
different substances were found, which is similar to 
what was found in samples from agricultural lands. 
However, the distribution of specific pharmaceuti-
cals is different. The pharmaceutical of the highest 
occurrence in urban areas is carbamazepine, which 
was found in 34 per cent of samples. In agricultural 
areas carbamazepine was found in only 13 per cent 
of samples. The second most common drug in urban 
areas is diclofenac, which was found in 10 per cent 
of sites. In agricultural areas the most common pain 
killer and anti-inflammatory drug was ibuprofen, 
which was found in 16 per cent of sampling points 
Table 3. Distribution of sites with positive detection of pharmaceuticals among different land use types at monitoring 
sites
Land use type  
at the sampling site
Number of sites Sites with pharmaceuticals among the same land use type
Sites with pharmaceuticals 
among all land use types
– % % %
Forests 23 14 30 4
Meadows 7 4 57 3
Industrial and urban areas (dense) 6 4 67 3
Agricultural areas 83 52 55 29
Urban areas with scattered buildings 41 26 59 15
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of that sampling group. Diclofenac was found only 
in 5 per cent of samples in agricultural areas.With 
respect to hormones, these were found at onefold 
sites and occurred in both agricultural and urban 
areas. There was definitely a higher detection of sul-
fonamides and antibiotics in agricultural areas than 
in urban areas. After summarising the number of 
positive detections of all antimicrobial agents, these 
were found at 57 per cent of sites in agricultural ar-
eas vs 34 per cent of urban areas and this probably 
reflects the wider use of veterinary drugs in rural 
areas.
Carbamazepine, the most commonly found 
drug during this study, was also found at sites 
located near meadows, which are also associated 
with agricultural areas and in forests, which most 
likely reflects poor sewage management at these 
sites. At sites classified as meadows there were 
also single detections of various anti-inflammato-
ry drugs such as diclofenac, ibuprofen, ketoprofen 
and flurbiprofen and also the veterinary antibiotics 
sulfametoxazole and enrofloxacin. The two last-
named were more often found at sites associated 
with forests.
4. Conclusions
The main aim of the present study was to deter-
mine whether active substances of pharmaceuticals 
do indeed pose a risk to groundwater resources in 
Poland, as suggested by studies in western Europe 
and the USA. Results of this study confirm the hy-
pothesis that the risk of pollution with pharmaceu-
ticals does exist also in Poland and needs further 
assessment and perhaps regulations at national lev-
el for the sake of future protection of groundwater 
resources. It needs to be noted; however, that sam-
ples were collected only once in each monitoring 
sites and as such represent temporary concentra-
tions. Their long-term presence, as well as the level 
of concentrations, need to be confirmed by repet-
itive, systematic sampling. The problem seems to 
be most relevant in rural areas, but urban planning 
with scattered building is nearly equally threatened 
by the problem. The distribution of active substanc-
es found during the present study with respect to 
land use at sampling locations indicates communal 
waste water sources to be the most probable sourc-
es of pollution with pharmaceuticals.
Table 4. Distribution of pharmaceuticals with respect to land use types at monitoring sites (number of positive detec-
tion, percentage of sites with positive detection within a given land use type)
Pharmaceuticals
Forests Meadows Industrial and urban areas (dense) Agricultural areas
Urban areas with scattered 
buildings
– % – % – % – % – %
Estrone 1 1 2 5
Estriol 1 2
17alfa-etynyloestradiol 1 1 1 2
17beta-estradiol 1 1
Testosterone 1 1 1 2
Metoprolol 1 2
Propranolol 1 1 2 5
Salbutamol 1 1
Diclofenac 1 14 4 5 4 10
Ibuprofen 1 14 2 33 13 16 3 7
Ketoprofen 1 14 3 4 1 2
Naproxen 3 4 1 2
Paracetamol 4 5
Flurbiprofen 1 4 1 14 3 4 2 5
Caffeine 1 2
Carbamazepine 4 17 3 43 1 17 11 13 14 34
Sulfadiazine 4 5 1 2
Sulfadimethoxine 8 10 2 5
Sulfamerazine 2 2 2 5
Sulfamethazine 4 5 1 2
Sulfamethoxazole 2 9 1 14 14 17 3 7
Sulfapyridine 5 6 2 5
Sulfathiazole 1 1
Enrofloxacin 2 9 1 14 1 17 7 8 3 7
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